Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INO-4500 Lassa Fever Vaccine in Healthy Volunteers
NCT04093076Phase 1Completed
- Sponsor
- Inovio Pharmaceuticals, Inc.
- Start
- Jan 2021
- Primary completion
- Oct 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of INO-4500 in Lassa fever (4 arms), sponsored by Inovio Pharmaceuticals, Inc. Primary endpoints: Number of Participants with Adverse Events (AEs) at Week 48, Number of Participants with Injection Site Reactions at Week 48 and 3 more. Started Jan 2021; status: completed.
02
Drugs
INO-4500
03
Conditions
Lassa fever
Beyond the preview
Go deeper on NCT04093076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04093076.